Pharmacokinetics, Safety and Tolerability of Once-Weekly Subcutaneous Semaglutide in Healthy Chinese Subjects: A Double-Blind, Phase 1, Randomized Controlled Trial.

Shi, Aixin; Xie, Panpan; Nielsen, Lasse Lykke; Skjøth, Trine Vang; He, Xuemei; Haugaard, Sine Pfeiffer

Shi, Aixin; Xie, Panpan; Nielsen, Lasse Lykke; Skjøth, Trine Vang; He, Xuemei; Haugaard, Sine Pfeiffer.

Afiliación

Shi A; Clinical Trial Center, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, People's Republic of China. aixins0302@126.com.
Xie P; Clinical Trial Center, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
Nielsen LL; Novo Nordisk A/S, Bagsværd, Denmark.
Skjøth TV; Novo Nordisk A/S, Bagsværd, Denmark.
He X; Clinical Trial Center, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
Haugaard SP; Novo Nordisk A/S, Bagsværd, Denmark.

Adv Ther ; 38(1): 550-561, 2021 01.

Article en En | MEDLINE | ID: mdl-33159658

Asunto(s)

Diabetes Mellitus Tipo 2; China; Método Doble Ciego; Péptidos Similares al Glucagón/efectos adversos; Voluntarios Sanos; Humanos; Hipoglucemiantes/efectos adversos

Palabras clave

Diabetes; Glucagon-like peptide-1 receptor agonist; Pharmacokinetics; Randomised controlled trial; Semaglutide; Steady state exposure

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans País/Región como asunto: Asia Idioma: En Revista: Adv Ther Asunto de la revista: TERAPEUTICA Año: 2021 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google